The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Conjugate Vaccine Market Insights and Forecast to 2028

Global Conjugate Vaccine Market Insights and Forecast to 2028

Publishing Date : Jan, 2022

License Type :
 

Report Code : 1658411

No of Pages : 94

Synopsis
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
Market Analysis and Insights: Global Conjugate Vaccine Market
Due to the COVID-19 pandemic, the global Conjugate Vaccine market size is estimated to be worth US$ 10340 million in 2022 and is forecast to a readjusted size of US$ 12490 million by 2028 with a CAGR of 3.2% during the review period. Fully considering the economic change by this health crisis, Hib Vaccine accounting for % of the Conjugate Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Children segment is altered to an % CAGR throughout this forecast period.
Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.
Global Conjugate Vaccine Scope and Segment
Conjugate Vaccine market is segmented by Type and by End Users. Players, stakeholders, and other participants in the global Conjugate Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by End Users for the period 2017-2028.
Segment by Type
Hib Vaccine
Meningococcal Vaccine
Pneumococcal Vaccine
Others
Segment by End Users
Children
Adult
By Company
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Index
1 Study Coverage
1.1 Conjugate Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Conjugate Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hib Vaccine
1.2.3 Meningococcal Vaccine
1.2.4 Pneumococcal Vaccine
1.2.5 Others
1.3 Market by End Users
1.3.1 Global Conjugate Vaccine Market Size Growth Rate by End Users, 2017 VS 2021 VS 2028
1.3.2 Children
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Conjugate Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Conjugate Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Conjugate Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Conjugate Vaccine Sales by Region
2.4.1 Global Conjugate Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Conjugate Vaccine by Region (2023-2028)
2.5 Global Conjugate Vaccine Revenue by Region
2.5.1 Global Conjugate Vaccine Revenue by Region (2017-2022)
2.5.2 Global Conjugate Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Conjugate Vaccine Sales by Manufacturers
3.1.1 Global Top Conjugate Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Conjugate Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Conjugate Vaccine in 2021
3.2 Global Conjugate Vaccine Revenue by Manufacturers
3.2.1 Global Conjugate Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Conjugate Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Conjugate Vaccine Revenue in 2021
3.3 Global Conjugate Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Conjugate Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Conjugate Vaccine Sales by Type
4.1.1 Global Conjugate Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Conjugate Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Conjugate Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Conjugate Vaccine Revenue by Type
4.2.1 Global Conjugate Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Conjugate Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Conjugate Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Conjugate Vaccine Price by Type
4.3.1 Global Conjugate Vaccine Price by Type (2017-2022)
4.3.2 Global Conjugate Vaccine Price Forecast by Type (2023-2028)
5 Market Size by End Users
5.1 Global Conjugate Vaccine Sales by End Users
5.1.1 Global Conjugate Vaccine Historical Sales by End Users (2017-2022)
5.1.2 Global Conjugate Vaccine Forecasted Sales by End Users (2023-2028)
5.1.3 Global Conjugate Vaccine Sales Market Share by End Users (2017-2028)
5.2 Global Conjugate Vaccine Revenue by End Users
5.2.1 Global Conjugate Vaccine Historical Revenue by End Users (2017-2022)
5.2.2 Global Conjugate Vaccine Forecasted Revenue by End Users (2023-2028)
5.2.3 Global Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
5.3 Global Conjugate Vaccine Price by End Users
5.3.1 Global Conjugate Vaccine Price by End Users (2017-2022)
5.3.2 Global Conjugate Vaccine Price Forecast by End Users (2023-2028)
6 North America
6.1 North America Conjugate Vaccine Market Size by Type
6.1.1 North America Conjugate Vaccine Sales by Type (2017-2028)
6.1.2 North America Conjugate Vaccine Revenue by Type (2017-2028)
6.2 North America Conjugate Vaccine Market Size by End Users
6.2.1 North America Conjugate Vaccine Sales by End Users (2017-2028)
6.2.2 North America Conjugate Vaccine Revenue by End Users (2017-2028)
6.3 North America Conjugate Vaccine Market Size by Country
6.3.1 North America Conjugate Vaccine Sales by Country (2017-2028)
6.3.2 North America Conjugate Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Conjugate Vaccine Market Size by Type
7.1.1 Europe Conjugate Vaccine Sales by Type (2017-2028)
7.1.2 Europe Conjugate Vaccine Revenue by Type (2017-2028)
7.2 Europe Conjugate Vaccine Market Size by End Users
7.2.1 Europe Conjugate Vaccine Sales by End Users (2017-2028)
7.2.2 Europe Conjugate Vaccine Revenue by End Users (2017-2028)
7.3 Europe Conjugate Vaccine Market Size by Country
7.3.1 Europe Conjugate Vaccine Sales by Country (2017-2028)
7.3.2 Europe Conjugate Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Conjugate Vaccine Market Size by Type
8.1.1 Asia Pacific Conjugate Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Conjugate Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Conjugate Vaccine Market Size by End Users
8.2.1 Asia Pacific Conjugate Vaccine Sales by End Users (2017-2028)
8.2.2 Asia Pacific Conjugate Vaccine Revenue by End Users (2017-2028)
8.3 Asia Pacific Conjugate Vaccine Market Size by Region
8.3.1 Asia Pacific Conjugate Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Conjugate Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Conjugate Vaccine Market Size by Type
9.1.1 Latin America Conjugate Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Conjugate Vaccine Revenue by Type (2017-2028)
9.2 Latin America Conjugate Vaccine Market Size by End Users
9.2.1 Latin America Conjugate Vaccine Sales by End Users (2017-2028)
9.2.2 Latin America Conjugate Vaccine Revenue by End Users (2017-2028)
9.3 Latin America Conjugate Vaccine Market Size by Country
9.3.1 Latin America Conjugate Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Conjugate Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Conjugate Vaccine Market Size by Type
10.1.1 Middle East and Africa Conjugate Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Conjugate Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Conjugate Vaccine Market Size by End Users
10.2.1 Middle East and Africa Conjugate Vaccine Sales by End Users (2017-2028)
10.2.2 Middle East and Africa Conjugate Vaccine Revenue by End Users (2017-2028)
10.3 Middle East and Africa Conjugate Vaccine Market Size by Country
10.3.1 Middle East and Africa Conjugate Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Conjugate Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Merck
11.4.1 Merck Corporation Information
11.4.2 Merck Overview
11.4.3 Merck Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Merck Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Walvax Biotechnology
11.5.1 Walvax Biotechnology Corporation Information
11.5.2 Walvax Biotechnology Overview
11.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Walvax Biotechnology Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Walvax Biotechnology Recent Developments
11.6 Royal (Wuxi) Bio-Pharmaceutical
11.6.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information
11.6.2 Royal (Wuxi) Bio-Pharmaceutical Overview
11.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
11.7 Bharat Biotech
11.7.1 Bharat Biotech Corporation Information
11.7.2 Bharat Biotech Overview
11.7.3 Bharat Biotech Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Bharat Biotech Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bharat Biotech Recent Developments
11.8 Zhifei Biologic
11.8.1 Zhifei Biologic Corporation Information
11.8.2 Zhifei Biologic Overview
11.8.3 Zhifei Biologic Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Zhifei Biologic Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Zhifei Biologic Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Conjugate Vaccine Industry Chain Analysis
12.2 Conjugate Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Conjugate Vaccine Production Mode & Process
12.4 Conjugate Vaccine Sales and Marketing
12.4.1 Conjugate Vaccine Sales Channels
12.4.2 Conjugate Vaccine Distributors
12.5 Conjugate Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Conjugate Vaccine Industry Trends
13.2 Conjugate Vaccine Market Drivers
13.3 Conjugate Vaccine Market Challenges
13.4 Conjugate Vaccine Market Restraints
14 Key Findings in The Global Conjugate Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
List of Tables
Table 1. Global Conjugate Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Hib Vaccine
Table 3. Major Manufacturers of Meningococcal Vaccine
Table 4. Major Manufacturers of Pneumococcal Vaccine
Table 5. Major Manufacturers of Others
Table 6. Global Conjugate Vaccine Market Size Growth Rate by End Users, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Conjugate Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Conjugate Vaccine Sales by Region (2017-2022) & (Million Unit)
Table 9. Global Conjugate Vaccine Sales Market Share by Region (2017-2022)
Table 10. Global Conjugate Vaccine Sales by Region (2023-2028) & (Million Unit)
Table 11. Global Conjugate Vaccine Sales Market Share by Region (2023-2028)
Table 12. Global Conjugate Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Conjugate Vaccine Revenue Market Share by Region (2017-2022)
Table 14. Global Conjugate Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Conjugate Vaccine Revenue Market Share by Region (2023-2028)
Table 16. Global Conjugate Vaccine Sales by Manufacturers (2017-2022) & (Million Unit)
Table 17. Global Conjugate Vaccine Sales Share by Manufacturers (2017-2022)
Table 18. Global Conjugate Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Conjugate Vaccine Revenue Share by Manufacturers (2017-2022)
Table 20. Conjugate Vaccine Price by Manufacturers (2017-2022) &(USD/Unit)
Table 21. Global Conjugate Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Conjugate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Conjugate Vaccine as of 2021)
Table 23. Conjugate Vaccine Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Conjugate Vaccine Product Offered
Table 25. Date of Manufacturers Enter into Conjugate Vaccine Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 28. Global Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 29. Global Conjugate Vaccine Sales Share by Type (2017-2022)
Table 30. Global Conjugate Vaccine Sales Share by Type (2023-2028)
Table 31. Global Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Conjugate Vaccine Revenue Share by Type (2017-2022)
Table 34. Global Conjugate Vaccine Revenue Share by Type (2023-2028)
Table 35. Conjugate Vaccine Price by Type (2017-2022) & (USD/Unit)
Table 36. Global Conjugate Vaccine Price Forecast by Type (2023-2028) & (USD/Unit)
Table 37. Global Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 38. Global Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 39. Global Conjugate Vaccine Sales Share by End Users (2017-2022)
Table 40. Global Conjugate Vaccine Sales Share by End Users (2023-2028)
Table 41. Global Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 42. Global Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 43. Global Conjugate Vaccine Revenue Share by End Users (2017-2022)
Table 44. Global Conjugate Vaccine Revenue Share by End Users (2023-2028)
Table 45. Conjugate Vaccine Price by End Users (2017-2022) & (USD/Unit)
Table 46. Global Conjugate Vaccine Price Forecast by End Users (2023-2028) & (USD/Unit)
Table 47. North America Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 48. North America Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 49. North America Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 52. North America Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 53. North America Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 54. North America Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 55. North America Conjugate Vaccine Sales by Country (2017-2022) & (Million Unit)
Table 56. North America Conjugate Vaccine Sales by Country (2023-2028) & (Million Unit)
Table 57. North America Conjugate Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Conjugate Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 60. Europe Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 61. Europe Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 64. Europe Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 65. Europe Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 66. Europe Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 67. Europe Conjugate Vaccine Sales by Country (2017-2022) & (Million Unit)
Table 68. Europe Conjugate Vaccine Sales by Country (2023-2028) & (Million Unit)
Table 69. Europe Conjugate Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Conjugate Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 72. Asia Pacific Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 73. Asia Pacific Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 76. Asia Pacific Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 77. Asia Pacific Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 78. Asia Pacific Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 79. Asia Pacific Conjugate Vaccine Sales by Region (2017-2022) & (Million Unit)
Table 80. Asia Pacific Conjugate Vaccine Sales by Region (2023-2028) & (Million Unit)
Table 81. Asia Pacific Conjugate Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Conjugate Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 84. Latin America Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 85. Latin America Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 88. Latin America Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 89. Latin America Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 90. Latin America Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 91. Latin America Conjugate Vaccine Sales by Country (2017-2022) & (Million Unit)
Table 92. Latin America Conjugate Vaccine Sales by Country (2023-2028) & (Million Unit)
Table 93. Latin America Conjugate Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Conjugate Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Conjugate Vaccine Sales by Type (2017-2022) & (Million Unit)
Table 96. Middle East and Africa Conjugate Vaccine Sales by Type (2023-2028) & (Million Unit)
Table 97. Middle East and Africa Conjugate Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Conjugate Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Conjugate Vaccine Sales by End Users (2017-2022) & (Million Unit)
Table 100. Middle East and Africa Conjugate Vaccine Sales by End Users (2023-2028) & (Million Unit)
Table 101. Middle East and Africa Conjugate Vaccine Revenue by End Users (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Conjugate Vaccine Revenue by End Users (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Conjugate Vaccine Sales by Country (2017-2022) & (Million Unit)
Table 104. Middle East and Africa Conjugate Vaccine Sales by Country (2023-2028) & (Million Unit)
Table 105. Middle East and Africa Conjugate Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Conjugate Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 107. Pfizer Corporation Information
Table 108. Pfizer Description and Major Businesses
Table 109. Pfizer Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. Pfizer Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Pfizer Recent Developments
Table 112. GSK Corporation Information
Table 113. GSK Description and Major Businesses
Table 114. GSK Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 115. GSK Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. GSK Recent Developments
Table 117. Sanofi Corporation Information
Table 118. Sanofi Description and Major Businesses
Table 119. Sanofi Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 120. Sanofi Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Recent Developments
Table 122. Merck Corporation Information
Table 123. Merck Description and Major Businesses
Table 124. Merck Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 125. Merck Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Merck Recent Developments
Table 127. Walvax Biotechnology Corporation Information
Table 128. Walvax Biotechnology Description and Major Businesses
Table 129. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 130. Walvax Biotechnology Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Walvax Biotechnology Recent Developments
Table 132. Royal (Wuxi) Bio-Pharmaceutical Corporation Information
Table 133. Royal (Wuxi) Bio-Pharmaceutical Description and Major Businesses
Table 134. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 135. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Royal (Wuxi) Bio-Pharmaceutical Recent Developments
Table 137. Bharat Biotech Corporation Information
Table 138. Bharat Biotech Description and Major Businesses
Table 139. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 140. Bharat Biotech Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Bharat Biotech Recent Developments
Table 142. Zhifei Biologic Corporation Information
Table 143. Zhifei Biologic Description and Major Businesses
Table 144. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 145. Zhifei Biologic Conjugate Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Zhifei Biologic Recent Developments
Table 147. Key Raw Materials Lists
Table 148. Raw Materials Key Suppliers Lists
Table 149. Conjugate Vaccine Distributors List
Table 150. Conjugate Vaccine Customers List
Table 151. Conjugate Vaccine Market Trends
Table 152. Conjugate Vaccine Market Drivers
Table 153. Conjugate Vaccine Market Challenges
Table 154. Conjugate Vaccine Market Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
List of Figures
Figure 1. Conjugate Vaccine Product Picture
Figure 3. Global Conjugate Vaccine Market Share by Type in 2021 & 2028
Figure 3. Hib Vaccine Product Picture
Figure 4. Meningococcal Vaccine Product Picture
Figure 5. Pneumococcal Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Conjugate Vaccine Market Share by End Users in 2021 & 2028
Figure 8. Children
Figure 9. Adult
Figure 10. Conjugate Vaccine Report Years Considered
Figure 11. Global Conjugate Vaccine Sales 2017-2028 (Million Unit)
Figure 12. Global Conjugate Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Conjugate Vaccine Revenue 2017-2028 (US$ Million)
Figure 14. Global Conjugate Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Conjugate Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Conjugate Vaccine Sales Market Share by Region (2023-2028)
Figure 17. North America Conjugate Vaccine Sales YoY (2017-2028) & (Million Unit)
Figure 18. North America Conjugate Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Conjugate Vaccine Sales YoY (2017-2028) & (Million Unit)
Figure 20. Europe Conjugate Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Conjugate Vaccine Sales YoY (2017-2028) & (Million Unit)
Figure 22. Asia-Pacific Conjugate Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Conjugate Vaccine Sales YoY (2017-2028) & (Million Unit)
Figure 24. Latin America Conjugate Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Conjugate Vaccine Sales YoY (2017-2028) & (Million Unit)
Figure 26. Middle East & Africa Conjugate Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Conjugate Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Conjugate Vaccine in the World: Market Share by Conjugate Vaccine Revenue in 2021
Figure 29. Global Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 31. Global Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 32. Global Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 33. Global Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 34. North America Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 35. North America Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 36. North America Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 37. North America Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 38. North America Conjugate Vaccine Sales Share by Country (2017-2028)
Figure 39. North America Conjugate Vaccine Revenue Share by Country (2017-2028)
Figure 40. U.S. Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 44. Europe Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 45. Europe Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 46. Europe Conjugate Vaccine Sales Share by Country (2017-2028)
Figure 47. Europe Conjugate Vaccine Revenue Share by Country (2017-2028)
Figure 48. Germany Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. France Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 56. Asia Pacific Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 57. Asia Pacific Conjugate Vaccine Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Conjugate Vaccine Revenue Share by Region (2017-2028)
Figure 59. China Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. India Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. Taiwan Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 68. Philippines Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 69. Latin America Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 70. Latin America Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 71. Latin America Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 72. Latin America Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 73. Latin America Conjugate Vaccine Sales Share by Country (2017-2028)
Figure 74. Latin America Conjugate Vaccine Revenue Share by Country (2017-2028)
Figure 75. Mexico Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Brazil Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 77. Argentina Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Conjugate Vaccine Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Conjugate Vaccine Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Conjugate Vaccine Sales Market Share by End Users (2017-2028)
Figure 81. Middle East and Africa Conjugate Vaccine Revenue Market Share by End Users (2017-2028)
Figure 82. Middle East and Africa Conjugate Vaccine Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Conjugate Vaccine Revenue Share by Country (2017-2028)
Figure 84. Turkey Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Conjugate Vaccine Revenue (2017-2028) & (US$ Million)
Figure 87. Conjugate Vaccine Value Chain
Figure 88. Conjugate Vaccine Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’